Group 2

USDA-APHIS Determines that Yield10 Bioscience’s Glufosinate Tolerant Camelina May Be Planted and Bred in the United States

Retrieved on: 
Wednesday, November 15, 2023
Yield10 Bioscience, Agriculture, EPA, Safety, Gene editing, USDA, BRS, Oil, CFR, Health, DHA, Group 2, Transport, Camelina

WOBURN, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that USDA-APHIS’s Biotechnology Regulatory Services (“BRS”) has determined that Yield10’s glufosinate tolerant Camelina sativa ("Camelina”) may be grown and bred in the United States. Yield10 submitted a Request for Regulatory Status Review (“RSR”) to the BRS under the SECURE Rule in June 2022 for glufosinate tolerant Camelina. The response from USDA-APHIS means that the agency does not consider the modified Camelina plant to be an increased plant pest risk as compared to unmodified Camelina and is therefore not subject to regulation under 7 CFR part 340 regulations. Yield10’s submission along with the USDA-APHIS BRS response is posted on the USDA’s website.

Key Points: 
  • Yield10 submitted a Request for Regulatory Status Review (“RSR”) to the BRS under the SECURE Rule in June 2022 for glufosinate tolerant Camelina.
  • “The regulatory clearance of glufosinate tolerant Camelina through USDA-APHIS represents a significant commercial milestone for Yield10,” said Kristi Snell, Ph.D., Chief Scientific Officer of Yield10 Bioscience.
  • We believe glufosinate tolerant Camelina will provide growers with new options for weed management allowing Camelina to fit seamlessly into crop rotations driving commercial adoption.
  • Yield10 is currently scaling-up seed inventory in anticipation of the commercial launch of glufosinate tolerant Camelina.

USDA-APHIS Determines that Yield10 Bioscience’s Stacked Herbicide Tolerant Camelina May Be Planted and Bred in the United States

Retrieved on: 
Wednesday, November 15, 2023
Yield10 Bioscience, Group 10 element, USDA, BRS, CFR, Sustainability, Consistency, Group 2, Soil, Agriculture, Management, Camelina, Ecology

In April 2023, Yield10 submitted Request for Confirmation of Regulatory Status packages to the BRS under the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (“SECURE”) Rule, for stacked HT Camelina varieties.

Key Points: 
  • In April 2023, Yield10 submitted Request for Confirmation of Regulatory Status packages to the BRS under the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (“SECURE”) Rule, for stacked HT Camelina varieties.
  • Yield10 is executing a program to develop and commercialize spring and winter Camelina varieties with stacked herbicide tolerance traits to achieve large-acreage adoption of the crop in North America.
  • “The regulatory clearance of our stacked HT Camelina represents another significant commercial milestone achieved by the Yield10 team, underscoring our commitment to establishing both technical and commercial leadership positions in Camelina,” said Kristi Snell, Ph.D., Chief Scientific Officer of Yield10 Bioscience.
  • “Earlier this year, we conducted our first field tests of stacked HT Camelina and reported positive results.

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Retrieved on: 
Thursday, November 9, 2023
Group 3, Hepatology, Safety, Immune system, Thyroiditis, RNA interference, AASLD, Risk, MVA, NUC, Patient, HBV, Clinical trial, Non-cirrhotic portal fibrosis, Liver, SOC, Autoimmune thyroiditis, CHB, Cancer, Nivolumab, Hepatitis, Group 2, Autoimmunity, Thyroid disease, Șaeș, Vaccine, Pharmaceutical industry, HBsAg

Alongside this, a late-breaking poster presentation with interim data from patients with chronic hepatitis B (CHB) from the Phase 2a AB-729-202 trial combining Arbutus Biopharma Corporation’s (NASDAQ: ABUS) RNAi therapeutic candidate, imdusiran (AB-729), with Barinthus Bio’s T cell stimulating immunotherapeutic candidate, VTP-300, and SoC NUC therapy.

Key Points: 
  • Alongside this, a late-breaking poster presentation with interim data from patients with chronic hepatitis B (CHB) from the Phase 2a AB-729-202 trial combining Arbutus Biopharma Corporation’s (NASDAQ: ABUS) RNAi therapeutic candidate, imdusiran (AB-729), with Barinthus Bio’s T cell stimulating immunotherapeutic candidate, VTP-300, and SoC NUC therapy.
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • Preliminary immunology data suggests HBV-specific T cell IFN-γ production was enhanced in patients receiving imdusiran plus VTP-300 compared to placebo.
  • Dr. Karen Sims, Chief Medical Officer of Arbutus Biopharma, commented, “Imdusiran consistently delivers compelling efficacy and safety data in multiple Phase 2a populations and combinations.

Global Clean Energy Announces Advancements in Herbicide Resistant Camelina Varieties

Retrieved on: 
Wednesday, November 15, 2023
Other Natural Resources, Environment, Sustainability, Agriculture, Environmental Health, Natural Resources, Genetics, Global Clean Energy Holdings, OTCQB, PPO, Carbon group, Farmer, Sustainable Oils, Group 2, Herbicide, Camelina

Global Clean Energy Holdings, Inc. (OTCQB:GCEH) today announced key advancements to accelerate adoption of Camelina sativa (camelina) in areas with higher use of two key herbicide groups, Group 2 and Group 14.

Key Points: 
  • Global Clean Energy Holdings, Inc. (OTCQB:GCEH) today announced key advancements to accelerate adoption of Camelina sativa (camelina) in areas with higher use of two key herbicide groups, Group 2 and Group 14.
  • A new Global Clean Energy camelina variety has confirmed resistance to imazamox and imazethapyr, the active ingredients in Beyond1 and Pursuit1 (Group 2 herbicides).
  • Global Clean Energy has over 20 years of camelina breeding history and is dedicated to developing and delivering superior, diverse genetics that provide farmers the most suitable high yielding camelina varieties for their growing conditions.
  • Global Clean Energy’s 20 patented camelina varieties include both spring and winter varieties with a suite of traits to enable camelina cultivation as an intermediate crop in a wide range of geographies and crop rotations.

Yield10 Bioscience Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina

Retrieved on: 
Wednesday, October 11, 2023
Sustainability, Livestock, HT, Rotation, United States Environmental Protection Agency, Contra, BRS, Weed control, Biofuel, Group 2, Consistency, Soil, Grain, Agriculture, Silviculture, Yield10 Bioscience, Camelina

WOBURN, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced recent advancements toward enabling weed control for Camelina cultivation and supporting grower adoption of the crop for production of low-carbon intensity feedstock oil for the biofuel market.

Key Points: 
  • Yield10 is establishing a leadership position in the development of herbicide tolerant (“HT”) Camelina to drive broad acceptance of the crop by growers.
  • “The Yield10 team is making significant progress toward our goal of launching elite herbicide tolerant Camelina for producing feedstock oil for the biofuels market,” said Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience.
  • We will also continue to execute on seed scale-up and regulatory activities in support of the planned commercial launch of our elite HT and stacked HT Camelina varieties.”
    Development of commercial quality herbicide tolerant Camelina.
  • Earlier this year Yield10 filed an RSR with USDA-APHIS (BRS) for Yield10’s stacked HT Camelina under the SECURE Rule.

The EBA second mandatory exercise on Basel III full implementation shows a significantly reduced impact on EU banks with shortfalls nearly fully absorbed

Retrieved on: 
Wednesday, September 27, 2023
Pillar, FRTB, Exercise, European Banking Authority, Group 1, Tier 1, EBA, European Commission, Group 2, Capital Requirements Regulation 2013, EUR, Report, COVID-19, Time, Buffer, Annex, CVA, Medical device, Bank, EU, European, Basel

The EBA second mandatory exercise on Basel III full implementation shows a significantly reduced impact on EU banks with shortfalls nearly fully absorbed

Key Points: 
  • The EBA second mandatory exercise on Basel III full implementation shows a significantly reduced impact on EU banks with shortfalls nearly fully absorbed
    26 September 2023
    The European Banking Authority (EBA) today published its second mandatory Basel III Monitoring Report which assesses the impact that Basel III full implementation will have on EU banks in 2028.
  • In terms of estimated capital shortfall, the impact of the reform has been nearly fully absorbed.
  • A separate Annex to the Report also includes the impact of the proposals for the EU implementation of Basel III under the revised Capital Requirements Regulation (CRR3).
  • - The Basel III Monitoring Report shows the results separately for Group 1 and Group 2 banks.

Yield10 Bioscience Announces Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Food, Travel, MPC, MSU, Marathon Petroleum, HT, BRS, Lead, Research, Mitsubishi Group, DOE, Government, Grain, Mitsubishi Corporation, Group 2, Plant, EPA, PHA, Weed control, Soil, Biofuel, Michigan State University, Webcast, Eicosapentaenoic acid, Gene, RSR, Renewable energy, Agriculture, Dietary supplement, Security (finance), Pharmaceutical industry, Yield10 Bioscience, Camelina

WOBURN, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the three and six months ended June 30, 2023.

Key Points: 
  • WOBURN, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the three and six months ended June 30, 2023.
  • "In the second quarter, we filed an RSR covering Camelina designed to produce the eicosapentaenoic acid ("EPA") component of omega-3 oil.
  • Net cash used by operating activities during the second quarter of 2023 was $3.1 million compared to $2.5 million used in the second quarter of 2022.
  • Yield10 Bioscience management will host a conference call today at 4:30 p.m. (ET) to discuss the second quarter 2023 results.

Yield10 Bioscience Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina, Supporting Large Acreage Production of Low-carbon Intensity Feedstock Oil for the Biofuel Market

Retrieved on: 
Wednesday, August 2, 2023
HT, IMI, BRS, Lead, Group 2, Plant, Weed control, Soil, RSR, Agriculture, Yield10 Bioscience, Camelina

WOBURN, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced positive results in the first field test of stacked herbicide tolerance (“HT”) traits in Camelina. These proprietary stacked HT Camelina varieties developed by Yield10 demonstrate tolerance to the application of an over-the-top herbicide for weed control as well as tolerance to Group 2 herbicide soil residues. These results represent a key advancement for supporting grower adoption of stacked HT Camelina for the biofuel feedstock market by enabling weed control and increased access to acreage previously treated with Group 2 herbicides. Yield10 is executing a program to develop and commercialize spring and winter Camelina varieties with stacked herbicide traits to achieve large acreage adoption of the crop in North America.

Key Points: 
  • WOBURN, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced positive results in the first field test of stacked herbicide tolerance (“HT”) traits in Camelina.
  • These proprietary stacked HT Camelina varieties developed by Yield10 demonstrate tolerance to the application of an over-the-top herbicide for weed control as well as tolerance to Group 2 herbicide soil residues.
  • These results represent a key advancement for supporting grower adoption of stacked HT Camelina for the biofuel feedstock market by enabling weed control and increased access to acreage previously treated with Group 2 herbicides.
  • Yield10 is executing a program to develop and commercialize spring and winter Camelina varieties with stacked herbicide traits to achieve large acreage adoption of the crop in North America.

Edge Compute Micro Flies on Griffon's Valiant Tactical Unmanned Aerial System (UAS)

Retrieved on: 
Monday, June 19, 2023
Graphics processing unit, United States Army Aviation Branch, Communication, Ben Goertzel, Atmosphere, UAS, Takeoff, Fire, Griffon Aerospace, Government, Valiant, Group 2, Robotics, Griffon, Artificial intelligence, Architecture, Mobile phone, Stratia

HUNTSVILLE, Ala., June 19, 2023 /PRNewswire/ -- Parry Labs has successfully flown their Edge Compute Micro (EC Micro) with a baseline Modular Open System Architecture (MOSA) software operating environment, Stratia, on the Griffon Aerospace Valiant platform.

Key Points: 
  • HUNTSVILLE, Ala., June 19, 2023 /PRNewswire/ -- Parry Labs has successfully flown their Edge Compute Micro (EC Micro) with a baseline Modular Open System Architecture (MOSA) software operating environment, Stratia, on the Griffon Aerospace Valiant platform.
  • EC Micro was designed as a versatile, ruggedized computing device to provide a unique combination of processing and precision time.
  • This milestone proves EC Micro, powered by Stratia, can provide industry leading processing power into Group 2, 3 and 4 vehicles at the edge, previously not available.
  • Parry Labs is proud to support Griffon Aerospace in their UAS endeavors and provide cutting edge technology to the warfighter.

Trillium Engineering announces collaboration with SightX, a technology company specializing in Edge AI

Retrieved on: 
Tuesday, April 25, 2023
Partnership, UAS, ISR, Intelligence, Group 2, Merlin, Acquisition, Map, AI, POL, DFW Skylink, Telemetry, Mobile phone, Engineering, Trillium

HOOD RIVER, Ore., April 25, 2023 /PRNewswire/ -- Trillium Engineering, a leading designer and manufacturer of high-quality imaging systems for manned and unmanned aircrafts performing intelligence, surveillance, and reconnaissance missions, announced a new collaboration with SightX, a deep-tech company specializing in Edge Artificial Intelligence (AI).

Key Points: 
  • HOOD RIVER, Ore., April 25, 2023 /PRNewswire/ -- Trillium Engineering, a leading designer and manufacturer of high-quality imaging systems for manned and unmanned aircrafts performing intelligence, surveillance, and reconnaissance missions, announced a new collaboration with SightX, a deep-tech company specializing in Edge Artificial Intelligence (AI).
  • SightX's groundbreaking Merlin software offers an advanced multi-object acquisition engine for mission-critical airborne applications at all wavelengths.
  • "This advancement will dramatically enhance the accuracy and efficiency of ISR missions," said Ryan O'Connor, Trillium's VP of Engineering.
  • "These features aren't currently available for Group 2 or 3 UAS gimbals," said Mark Mirelez, CEO of Trillium Engineering.